Exploring the Dynamics of ctDNA as a Predictive Biomarker of Recurrent Disease in Post-Operative Patients with Colorectal Cancer (CRC)

home / between-the-lines / exploring-the-dynamics-of-ctdna-as-a-predictive-biomarker-of-recurrent-disease-in-post-operative

Gastrointestinal medical oncologists review recent clinical research and have a comprehensive discussion on the use of circulating tumor DNA (ctDNA) as a predictive biomarker in patients with colorectal cancer.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 1: The Role of ctDNA as a Biomarker in Colorectal Cancer

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 8th 2024

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 2: Key Findings from the INTERCEPT Study

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 8th 2024

GI medical oncologists review recent findings from the INTERCEPT study evaluating the prognostic performance of circulating tumor DNA in clinical practice.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 3: Frequency of ctDNA Testing and Future Directions in Detecting MRD

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 15th 2024

Experts on colorectal cancer share insights on optimizing the frequency of ctDNA detection and discuss potential ways to overcome challenges associated with MRD detection.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 4: Comprehensive Insights on GALAXY Study in CIRCULATE-Japan

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 15th 2024

Daniel H. Ahn, DO, and Stacey A. Cohen, MD, engage in a comprehensive discussion on recent findings from the GALAXY study in CIRCULATE-Japan.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 5: Is Clearance of ctDNA an Acceptable Surrogate End Point?

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 22nd 2024

Medical oncologists discuss whether ctDNA clearance can serve as an acceptable surrogate end point in the treatment of patients with colorectal cancer.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 6: Recent Data from BESPOKE-CRC

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 22nd 2024

Colorectal cancer specialists review recent updates from BESPOKE-CRC evaluating the utilization of circulating tumor DNA for informing adjuvant therapy in patients with colorectal cancer.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 7: DYNAMIC Clinical Trial: ctDNA Guiding Adjuvant Therapy in Stage II Colorectal Cancer

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 29th 2024

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, provide comprehensive insights on the DYNAMIC clinical trial, an interventional study of circulating tumor DNA in colorectal cancer.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 8: COBRA: Rates of ctDNA Clearance in Assay-Directed Therapy

Stacey A. Cohen, MD;Daniel H. Ahn, DO
July 29th 2024

Daniel H. Ahn, DO, and Stacey A. Cohen, MD, discuss the COBRA clinical trial, which evaluated rates of ctDNA clearance in patients with colorectal cancer receiving assay-directed therapy.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 9: Optimizing Clinical Research and Patient Perceptions of ctDNA Testing

Stacey A. Cohen, MD;Daniel H. Ahn, DO
August 5th 2024

Experts on colorectal cancer brainstorm ways to optimize clinical research on ctDNA and discuss patient perceptions of ctDNA testing.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides

EP. 10: Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer

Stacey A. Cohen, MD;Daniel H. Ahn, DO
August 5th 2024

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.